Adenocarcinoma pancreas

5 trials 3 recruiting MedDRA PT
5 Registered trials
3 Recruiting
5 Unique sponsors
7 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
Mechanism of action (INN-stem analysis)
Unknown / small molecule 6 substances
Taxane 1 substance
Phase II/III: 1 Phase II: 3 Phase I (First in Human): 1

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase II/III

1 trial
  • Silexion Therapeutics Ltd. Commercial
    SIL204
    2025-525157-39-00 1 country n=10
    Pending

Phase II

3 trials
  • Novartis Pharma AG Commercial
    177LU-FAP-2286; CALCIUM FOLINATE; FAP-2286; PACLITAXEL ALBUMIN-BOUND
    2023-508995-12-01 4 countries 2025 n=36
    Recruiting
  • Theriva Biologics S.L. Commercial
    GENETICALLY MODIFIED HUMAN ADENOVIRUS ENCODING HUMAN PH20 HYALURONIDASE
    2026-525566-21-00 1 country n=6 Orphan
    Pending
  • Universitaetsklinikum Ulm AöR Academic
    IMP not specified
    2023-510490-34-00 1 country 2025 n=92
    Recruiting

Phase I (First in Human)

1 trial
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Silexion Therapeutics Ltd. Commercial 1 Phase II/III 0
Novartis Pharma AG Commercial 1 Phase II 1
Theriva Biologics S.L. Commercial 1 Phase II 0
BioNTech SE Commercial 1 Phase I (First in Human) 1
Universitaetsklinikum Ulm AöR Academic 1 Phase II 1
New trials by year
2025
2
2026
1
← All indication landscapes